MOTS-c / Tesamorelin.
A metabolic and body-composition combination targeting both cellular fuel use and visceral fat.
2 mg / 3 mg per mL · single-vial injectablePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Patients with stubborn visceral or midsection fat
- Patients with insulin-resistance tendencies or metabolic slowdown
- Patients pursuing body recomposition rather than simple weight loss
- Patients wanting both energy and aesthetic improvements
This isn't for you if
Tesamorelin can affect glucose regulation; baseline metabolic labs are recommended. Not appropriate during pregnancy, breastfeeding, or with active malignancy.
MOTS-c / Tesamorelin
This combination pairs MOTS-c, a mitochondrial-derived peptide that regulates metabolism at the cellular level, with Tesamorelin — the FDA-approved GHRH analog with the strongest evidence for visceral fat reduction. Two complementary mechanisms in a single nightly injection.
Mechanism and fit.
MOTS-c works inside the mitochondria to improve how cells use glucose and fat for energy, supporting metabolic flexibility and insulin sensitivity. Tesamorelin drives the nighttime GH pulse that targets visceral fat and supports lean-mass preservation. Together they address both the cellular efficiency side and the deep-fat-burning side of body recomposition.
Who this is typically for.
- Patients with stubborn visceral or midsection fat
- Patients with insulin-resistance tendencies or metabolic slowdown
- Patients pursuing body recomposition rather than simple weight loss
- Patients wanting both energy and aesthetic improvements
What patients
most often ask.
How is this different from GLP-1 therapy?
GLP-1 medications reduce appetite and slow gastric emptying — they primarily change how much you eat. This combination changes how your body uses fuel and where it stores fat. They address different problems and can be used together in some protocols.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Patients with stubborn visceral or midsection fat</li><li>Patients with insulin-resistance tendencies or metabolic slowdown</li><li>Patients pursuing body recomposition rather than simple weight loss</li><li>Patients wanting both energy and aesthetic improvements</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingOnce nightly subcutaneously, typically 5 nights on / 2 nights off.
- Typical durationInitial cycle 8–12 weeks.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering MOTS-c / Tesamorelin, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.